Merck Kgaa Unsp ADR (MKGAY) 56.4500 $MKGAY
Threshold Pharmaceuticals' Partner Merck KGaA, Darmstadt, Germany Initiates Phase 1 Dose Escalation Study of TH-302 in Combination With Gemcitabine and Nab-paclitaxel (Abraxane(R)) in Pancreatic Cancer
Marketwire - Thu Mar 27, 6:00AM CDT
Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that Threshold's partner Merck KGaA, Darmstadt, Germany, through its biopharmaceutical division, has initiated a Phase 1 dose escalation study assessing the safety, tolerability and anti-tumor activity of the investigational hypoxia-targeted drug TH-302 in combination with gemcitabine and nab-paclitaxel (Abraxane(R)) in patients with previously untreated, locally advanced unresectable or metastatic pancreatic adenocarcinoma.
Smoking Cessation Partnering 2009-2014 Report Features Everything a Prospective Dealmaker Needs to Know About Partnering
M2 - Thu Mar 27, 5:31AM CDT
Research and Markets (http://www.researchandmarkets.com/research/vvh8g5/smoking_cessation) has announced the addition of the "Smoking Cessation Partnering 2009-2014" report to their offering. Smoking Cessation Partnering 2009-2014 report provides understanding and access to the smoking partnering deals and agreements entered into by the worlds leading healthcare companies. - Trends in smoking cessation partnering deals - Top smoking deals by value - Deals listed by company A-Z, industry sector, stage of development, technology type The report provides an analysis of smoking cessation partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors smoking cessation technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases do not. Companies Mentioned: Normal 0 false false false EN-IE X-NONE X-NONE Abbott Actavis Astellas AstraZeneca Baxter International Boehringer Ingelheim Bristol-Myers Squibb Celgene Daiichi Sankyo Dainippon Sumitomo Eisai Eli Lilly Forest Laboratories GlaxoSmithKline Hospira Johnson & Johnson Kyowa Hakko Kirin Lundbeck Merck KGaA Novo Nordisk Otsuka Pfizer Roche Sanofi Shire Takeda Teva Valeant Warner Chilcott Watson For more information visit http://www.researchandmarkets.com/research/vv..._cessation About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Hearing Disorders Partnering 2009-2014 Study Provides Understanding and Access to the Hearing Disorders Partnering Deals and Agreements
M2 - Wed Mar 26, 11:05AM CDT
Research and Markets (http://www.researchandmarkets.com/research/dljhf4/hearing_disorders) has announced the addition of the "Hearing Disorders Partnering 2009-2014" report to their offering. Hearing Disorders Partnering 2009-2014 report provides understanding and access to the Hearing disorders partnering deals and agreements entered into by the worlds leading healthcare companies. - Trends in Hearing disorders partnering deals - Top Hearing disorders deals by value - Deals listed by company A-Z, industry sector, stage of development, technology type Hearing Disorders Partnering 2009-2014 provides understanding and access to the Hearing disorders partnering deals and agreements entered into by the worlds leading healthcare companies. The report provides an analysis of hearing disorders partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors Hearing disorders technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. Companies Mentioned: Normal 0 false false false EN-IE X-NONE X-NONE Abbott Actavis Aspen Pharmacare Astellas AstraZeneca Baxter International Bayer Boehringer Ingelheim Bristol-Myers Squibb Celgene CSL Daiichi Sankyo Eli Lilly Forest Laboratories GlaxoSmithKline Hospira Johnson & Johnson Kyowa Hakko Kirin Lundbeck Merck KGaA Mitsubishi Tanabe Novo Nordisk Otsuka Pfizer Roche Sanofi Takeda Teva Valeant Watson For more information visit http://www.researchandmarkets.com/research/dl...g_disorder About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Preventative Medicine Partnering 2009-2014 Report Out Now
M2 - Wed Mar 26, 11:00AM CDT
Research and Markets (http://www.researchandmarkets.com/research/xjvn7k/preventative) has announced the addition of the "Preventative Medicine Partnering 2009-2014" report to their offering. Preventative Medicine Partnering 2009-2014 report provides understanding and access to the preventative medicine partnering deals and agreements entered into by the worlds leading healthcare companies. - Trends in preventative medicine partnering deals - Top preventative medicine deals by value - Deals listed by company A-Z, industry sector, stage of development, technology type Preventative Medicine Partnering 2009-2014 provides understanding and access to the preventative medicine partnering deals and agreements entered into by the worlds leading healthcare companies. The report provides an analysis of preventative medicine partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors preventative medicine technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases do not. In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of preventative medicine technologies and products. Companies Mentioned: -Abbott -AstraZeneca -Baxter International -Bayer -Boehringer Ingelheim -Bristol-Myers Squibb -CSL -Daiichi Sankyo -Eli Lilly -Endo Pharmaceuticals -Forest Laboratories -Galderma -Gilead Sciences -Hospira -Johnson & Johnson -Kyowa Hakko Kirin -Lundbeck -Merck KGaA -Mitsubishi Tanabe -Novartis -Novo Nordisk -Otsuka -Pfizer -Roche -Sanofi -Shire -Takeda -Valeant -Warner Chilcott -Watson For more information visit http://www.researchandmarkets.com/research/xj...eventative About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Kemira Oyj: Jari Paasikivi elected as new Chairman of the Board of Directors in the AGM, EUR 0.53 dividend approved
Thomson Reuters ONE - Mon Mar 24, 8:31AM CDT
The Annual General Meeting of Kemira Oyj approved the Board of Directors proposal of EUR 0.53 dividend per share for the financial year 2013. The Annual General Meeting elected six members (previously five) to the Board of Directors. Annual General Meeting reelected Winnie Fok, Juha Laaksonen, Jari Paasikivi and Kerttu Tuomas and elected Wolfgang Buchele and Timo Lappalainen as new members. Jari Paasikivi was elected as the Board's Chairman and Kerttu Tuomas was elected as the Vice Chairman.
Global Specialty Chemicals Market 2014-2018: Trend of Mergers and Acquisitions Expected to Continue in the High Growth Areas of Latin America and the APAC Region
M2 - Fri Mar 07, 6:32AM CST
Research and Markets (http://www.researchandmarkets.com/research/kqdpg3/global_specialty) has announced the addition of the "Global Specialty Chemicals Market 2014-2018" report to their offering. The analysts forecast the Global Specialty Chemicals market to grow at a CAGR of 5.16 percent over the period 2013-2018. One of the key factors contributing to this market growth is the growing demand for specialty chemicals products in the rapidly developing countries of the APAC region. The Global Specialty Chemicals market has also been witnessing the increase in mergers and acquisitions through which key players in the market are increasing their penetration in the emerging economies. However, the increasingly stringent health and environmental regulations could pose a challenge to the growth of this market. Key vendors dominating this space are 3M Company, AkzoNobel NV, Arkema SA, BASF SE, Bayer AG, Clariant AG, Dow Chemical Co., Evonik Industries Inc., Ecolab Inc., E. I. du Pont de Nemours and Co., Henkel AG & Co. KGaA, Koninklijke DSM NV, PPG Industries Inc., Solvay-Rhodia, and Syngenta AG. Other vendors mentioned in the report are Ashland Inc., Avery Dennison Corp., DIC Corp., Eastman Chemical Co., Givaudan SA, Honeywell International Inc., Huntsman Corp., Lonza Group, Lubrizol Corp., Merck KGaA, Momentive Performance Materials Holdings Inc., Monsanto Co., RPM International Inc., Sherwin-Williams Co., Shin-Etsu Chemical Co. Ltd., Toray Industries Inc., Valspar Corp., and Wacker Chemie AG. Commenting on the report, an analyst from the team said: Many SMEs involved in chemical manufacturing are effective in the production of specialty chemicals for niche markets, though they lack in logistics for manufacturing specialty chemicals in bulk. Since the Specialty Chemicals market is highly fragmented, the key players are trying to gain more market share through the mergers and acquisitions of smaller firms. This trend will help the large vendors to grow and improve their networks at a faster pace. Moreover, the mergers and acquisitions strategy will help the bigger players to penetrate the markets in the emerging economies of Latin America and the APAC region. Global chemical manufacturers that have a large geographic presence, diversified product portfolio, and technical expertise for providing VAS are preferred by large industrial consumers. The mergers and acquisitions strategy serves all three main purposes of improving efficiency, diversifying product portfolio, and expanding the vendors' geographic presence. For more information visit http://www.researchandmarkets.com/research/kq..._specialty About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Threshold Pharmaceuticals Reports Fourth Quarter and Year End 2013 Financial and Operational Results
Marketwire - Thu Mar 06, 6:00AM CST
Threshold Pharmaceuticals, Inc. (NASDAQ: THLD), today reported financial results for the fourth quarter and year ended December 31, 2013 and reported on clinical development objectives for TH-302, the Company's investigational hypoxia-targeted drug, which is currently being evaluated in two pivotal Phase 3 clinical trials, one in patients with advanced soft tissue sarcoma and the other in patients with advanced pancreatic cancer. Revenue for the fourth quarter and year ended December 31, 2013 was $3.2 million and $12.5 million, respectively. Net loss for the fourth quarter ended December 31, 2013 was $7.6 million, which included the operating loss of $7.8 million and non-cash income of $0.2 million related to changes in the fair value of the Company's outstanding and exercised warrants that was classified as other income (expense). Net loss for the year ended December 31, 2013 was $28.4 million, which included the operating loss of $26.0 million and non-cash expense of $2.3 million related to changes in the fair value of the Company's outstanding and exercised warrants. As of December 31, 2013, Threshold had $82.0 million in cash, cash equivalents and marketable securities, with no debt outstanding. Subsequent to December 31, 2013, Threshold received a $12.5 million milestone payment, which was earned during the fourth quarter of 2013, under its global license and co-development agreement with Merck KGaA, Darmstadt, Germany. The agreement includes an option for Threshold to co-commercialize TH-302 in the U.S.
Concise Analysis of the Future Prospects of Global Personalized Medicine Market
M2 - Tue Mar 04, 5:49AM CST
Research and Markets (http://www.researchandmarkets.com/research/zpctsr/future_prospects) has announced the addition of the "Concise Analysis of the Future Prospects of Global Personalized Medicine Market" report to their offering. Over the years, the Global Personalized Medicine market has been witnessing the emergence of various tools and technologies from the reputed vendors. For instance, AssureRx Health Inc. launched GeneSightRx ADHD in May 2012, a personalized medicine test for the growing number of children and adults diagnosed with ADHD. Moreover, Bristol-Myers Squibb Co. collaborated with MMRF in December 2012 for advanced personalized medicine for multiple Myeloma. Further, Alacris Theranostics GmbH entered into an agreement with GlaxoSmithKline plc in November 2012 to use ModCell system for early stage cancer research. Further, AltheaDx Inc. launched FLT3 Mutation Assay in October 2012. Agendia N.V. launched ColoPrint microarray-based 18-gene expression signature in June 2012 for predicting the risk of distant recurrence for stage II colon cancer patients. The European Medicines Agency approved Zelboraf, manufactured by F. Hoffmann-La Roche Ltd., in December 2011. Key Topics Covered: 1. Executive Summary 2. List of Abbreviations 3. Introduction 4. Market Research Methodology 5. Scope of the Report 6. Market Landscape 7. Geographical Segmentation 8. Key Leading Countries 9. Vendor Landscape 10. Buying Criteria 11. Market Growth Drivers 12. Drivers and their Impact 13. Market Challenges 14. Impact of Drivers and Challenges 15. Market Trends 16. Key Vendor Analysis 17. Other Reports in this Series Companies Mentioned: - Abbott Laboratories - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Co. - Celgene Corp. - Daiichi Sankyo Co. Ltd. - Danaher Corp. - Eli Lilly and Co. - Evotec AG - F. Hoffmann-La Roche Ltd. - GE Healthcare Ltd. - Genelex Corp. - GlaxoSmithKline plc - Hologic Inc. - Johnson & Johnson - Laboratory Corporation of America Holdings - Life Technologies Corp. - Merck KGaA - Mitsubishi Tanabe Pharma Corp. - Myriad Genetics Inc. - Novartis AG - Novartis AG - PerkinElmer Inc. - Pfizer Inc. - Pfizer Inc. - Quest Diagnostics Inc. - Sanofi S.A. - Sanofi S.A. - Siemens Healthcare - Sigma-Aldrich Corp. - Takeda Pharmaceutical Co. Ltd. - Teva Pharmaceutical Industries Ltd. - Thermo Fisher Scientific Inc. - Transgenomic Inc. For more information visit http://www.researchandmarkets.com/research/zp..._prospects
Infectives Partnering Terms and Agreements Report - 2014 Edition
M2 - Tue Feb 25, 9:46AM CST
Research and Markets (http://www.researchandmarkets.com/research/dxxcsm/infectives) has announced the addition of the "Infectives Partnering Terms and Agreements" report to their offering. The Infectives Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the infectives partnering deals and agreements entered into by the worlds leading healthcare companies. The report provides a detailed understanding and analysis of how and why companies enter infectives partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors infectives technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases do not. Key Topics Covered: Executive Summary Chapter 1 - Introduction Chapter 2 - Trends in infectives dealmaking Chapter 3 - Leading infectives deals Chapter 4 - Bigpharma infectives deals Chapter 5 - Infectives partnering contracts directory Chapter 6 - Infectives dealmaking by indication Chapter 7 - Partnering resource center Companies Mentioned - Abbott - Actavis - Aspen Pharmacare - AstraZeneca - Baxter International - Bayer - Biogen Idec - Boehringer Ingelheim - Bristol-Myers Squibb - Dainippon Sumitomo - Eisai - Eli Lilly - Gilead Sciences - GlaxoSmithKline - Grifols - Hospira - Johnson & Johnson - Kyowa Hakko Kirin - Merck & Co - Merck KGaA - Mitsubishi Tanabe - Novartis - Novo Nordisk - Pfizer - Roche - Sanofi - Servier - Teva - Warner Chilcott - Watson For more information visit http://www.researchandmarkets.com/research/dxxcsm/infectives
TransCelerate BioPharma Inc. Names Annalisa Jenkins as Chair of Its Board of Directors
PR Newswire - Tue Feb 25, 8:00AM CST
TransCelerate BioPharma Inc. ("TransCelerate") today announced the appointment of Annalisa Jenkins, MBBS, MRCP, Executive Vice President and Head of Global Research and Development at Merck Serono (biopharma division of Merck KGaA, Darmstadt, Germany), as Chair of its Board of Directors, effective immediately. Dr. Jenkins, who previously served as a member of the Board of Directors, will work closely with TransCelerate CEO Dr. Dalvir Gill to further the organization's goal of helping the industry expedite the delivery of more high quality medicines to patients. Dr. Jenkins will succeed Paul Stoffels, MD, who had served as the interim Chairman of the Board.
Concise Analysis of the International Chromatography Reagents Market - Forecasts to 2018
M2 - Fri Feb 21, 2:52AM CST
Research and Markets (http://www.researchandmarkets.com/research/qgpjjl/chromatography) has announced the addition of the "Concise Analysis of the International Chromatography Reagents Market - Forecasts to 2018" report to their offering. The market has witnessed a large number of advancements in the design of columns and the development of better performing resins and reagents. The global market is valued at $4,598.0 million in 2013 and is expected to reach $7,609.3 million by 2018, at a CAGR of 10.6%. This report categorizes the market into two broad segments based on application, namely,analytical CR and bioprocess/preparative chromatography reagents. These two application segments are further categorized into CR by type, technique, end users, and geography. For analytical applications, the market by type is categorized into silylation reagents, alkylation reagents, acylation reagents, ion-pairing reagents, solvents, buffers, and solid support. Solvents dominate the market for analytical applications in 2013, closely followed by solid support. The market by type for bioprocess/preparative applications is broadly categorized into solvents, buffers, and solid support.Solid support dominated the market in 2013 with a market share of around 49% of the global bio-process/preparative market. The market by technique is categorized into column and planar chromatography reagents based on bed shape; gas, liquid, and supercritical phase CR based on physical state of mobile phase; and adsorption, partition, ion-exchange, size exclusion and affinity CR based on separation mechanism. Key Topics Covered: 1 Introduction 2 Executive Summary 3 Market Overview 4 Global Market, By Type 5 Global Market,By Bed Shape 6 Global Market,By Physical State Of Mobile Phase 7 Global Market, By Separation Mechanism 8 Global Market, By End Users 9 Geographic Analysis 10 Competitive Landscape 11 Company Profiles Companies Mentioned: - Agilent Technologies - Becton, Dickinson And Company - Bio-Rad Laboratories, INC - Emd Millipore/Merck Millipore (A Divison Of Merck KGAA) - GE Healthcare - Helena Laboratories - Life Technologies - Pall Corporation - Phenomenex, INC - Regis Technologies - Sigma-Aldrich Corporation - Thermo Fisher Scientific - Tosoh Corporation - VWR International - WR Grace & CO - Waters Corporation For more information visit http://www.researchandmarkets.com/research/qg...matography
2013 Report on Biotechnology Deals and Alliances Includes the Most Up to Date Deal and Company Data
M2 - Mon Feb 17, 6:42AM CST
Research and Markets (http://www.researchandmarkets.com/research/9lxjp7/biotechnology) has announced the addition of the "Biotechnology Deals and Alliances of 2013" report to their offering. Using these reports, dealmakers will effectively and efficiently gain insight into the partnering activities of the past year. The report series allows you to view all the partnering and alliances deals announced worldwide. The initial chapters of this report provide an orientation of 2013's dealmaking and business activities. Chapter 1 provides an overview of the trends in dealmaking during 2013 covering trends by deal type, stage of development, technology type and therapeutic indication. Chapter 2 provides a review of the leading deals during 2013. Deals are listed by headline value, signed by Biotechnology and bigbiotech, and most active Biotechnology. Where the deal has an agreement contract published at the SEC a link provides online access to the contract. Chapter 3 provides a comprehensive listing of the top 50 Biotechnology companies with a brief summary followed by a comprehensive listing of 2013 deals, as well as contract documents available in the public domain. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. Chapter 4 provides a comprehensive directory of all partnering deals announced during 2013. In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of technologies and products during 2013. Companies Mentioned: - Abbott - Actavis - Astellas - AstraZeneca - Baxter International - Boehringer Ingelheim - Bristol-Myers Squibb - Celgene - Daiichi Sankyo - Eli Lilly - Endo Pharmaceuticals - Forest Laboratories - GlaxoSmithKline - Grifols - Hospira - Johnson & Johnson - Kyowa Hakko Kirin - Lundbeck - Merck KGaA - Novo Nordisk - Otsuka - Pfizer - Roche - Sanofi - Shire - Takeda - Teva - Valeant - Warner Chilcott - Watson For more information visit http://www.researchandmarkets.com/research/9l...technology About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Cartilage Degeneration - Pipeline Review, H2 2013 Research Report
M2 - Mon Feb 17, 3:39AM CST
Research and Markets (http://www.researchandmarkets.com/research/hzb6kb/cartilage) has announced the addition of the "Cartilage Degeneration - Pipeline Review, H2 2013" report to their offering. 'Cartilage Degeneration - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Cartilage Degeneration, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Cartilage Degeneration. Scope - A snapshot of the global therapeutic scenario for Cartilage Degeneration. - A review of the Cartilage Degeneration products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Cartilage Degeneration pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: Introduction Cartilage Degeneration Overview Therapeutics Development Clinical Stage Products Early Stage Products Cartilage Degeneration - Products under Development by Companies Cartilage Degeneration - Companies Involved in Therapeutics Development Cartilage Degeneration - Therapeutics Assessment Drug Profiles sprifermin - Drug Profile Chondrogen - Drug Profile MSB-CAR-001 - Drug Profile AOD-9604 - Drug Profile THR-166 - Drug Profile ST-03 - Drug Profile Cartilage Degeneration - Recent Pipeline Updates Appendix List of Tables List of Figures Companies Mentioned Sanofi Merck KGaA Mesoblast Limited Calzada Limited Thrasos, Inc. For more information visit http://www.researchandmarkets.com/research/hzb6kb/cartilage About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
ABPI, Merck KGaA, Sanofi and Many More Now Confirmed for SMi Group Big Data in Pharma Event
PRWeb - Tue Feb 04, 5:01AM CST
Two-day event to take place 12th - 13th May 2014 in London featuring leading pharma and biotech experts.The event will aim to help companies understand how to leverage Big Data by exploiting its potential to create better medicine and generate new revenue streams.
Shell to stop Alaska exploratory drilling in 2014
EFE News Services - Thu Jan 30, 1:22PM CST
Royal Dutch Shell will halt its exploration program for the U.S. state of Alaska in 2014, new CEO Ben van Beurden announced Thursday.
SMi Group announces inaugural Big Data in Pharma event
PRWeb - Fri Jan 24, 7:10AM CST
The SMi Group has announced the launch of its inaugural Big Data in Pharma event in response to market demand. The two-day event will aim to help companies understand how to leverage Big Data by exploiting its potential to create better medicine and generate new revenue streams.
'Why De-Registered Parties Joined PDP'
by Misbahu Bashir - All Africa Global Media - Tue Jan 21, 3:32AM CST
Chairman of the defunct United Nigeria Peoples Party (UNPP) Alhaji Inuwa Ahmed, yesterday at a media briefing in Kaduna explained why 23 de-registered political parties joined the ruling People's Democratic Party (PDP).
Stria Unveils Cost-Cutting Lithium Processing Technologies for Its Pontax and Wilcox Lithium Projects
Marketwire Canada - Tue Jan 14, 8:13AM CST
Stria Capital Inc. (TSX VENTURE:SRA) ("Stria") owner of the Pontax Lithium and Wilcox Lithium Projects, (see news release dated January 6, 2014 available at www.sedar.com), in Canada and the United States, announced today its plans to introduce proprietary on-site processing technologies that produce high purity lithium chloride directly from spodumene ore on an environmentally sustainable, cost-reduced basis.
Personalized Medicine in Oncology Partnering Terms and Agreements Report 2014
M2 - Fri Jan 10, 8:18AM CST
Research and Markets (http://www.researchandmarkets.com/research/f8nt2k/personalized) has announced the addition of the "Personalized Medicine in Oncology Partnering Terms and Agreements" report to their offering. The Personalized Medicine in Oncology Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the personalized medicine in oncology partnering agreements entered into by the worlds leading healthcare companies. The report provides a detailed understanding and analysis of how and why companies enter personalized medicine in oncology partnering deals. The majority of deals are discovery stage whereby the licensee obtains a right or an option right to license the licensors personalized medicine technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not. Key Topics Covered: Chapter 1 - Introduction Chapter 2 - Trends in personalized medicine in oncology dealmaking Chapter 3 - Leading personalized medicine in oncology deals Chapter 4 - Big pharma personalized medicine in oncology deals Chapter 5 - Personalized medicine in oncology dealmaking directory Chapter 6 - Personalized medicine in oncology dealmaking directory by specific technology type Chapter 7 - Partnering resource center Companies Mentioned - Abbott - Amgen - Astellas - AstraZeneca - Bayer - Biogen Idec - Boehringer Ingelheim - Bristol-Myers Squibb - Celgene - Eisai - Eli Lilly - Gilead Sciences - GlaxoSmithKline - Johnson & Johnson - Merck & Co - Merck KGaA - Novartis - Pfizer - Roche - Sanofi - Servier - Teva For more information visit http://www.researchandmarkets.com/research/f8...rsonalized
Vaccine Partnering Terms and Agreements - 2014 Report
M2 - Fri Jan 10, 4:25AM CST
Research and Markets (http://www.researchandmarkets.com/research/qvn7n4/vaccine) has announced the addition of the "Vaccine Partnering Terms and Agreements" report to their offering. The report provides comprehensive understanding and unprecedented access to the vaccine partnering deals and agreements entered into by the worlds leading healthcare companies. The report provides a detailed understanding and analysis of how and why companies enter vaccine partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors vaccine technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. The report also includes adjuvant deals and alliances. This report contains over 1,100 links to online copies of actual vaccine deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal. Vaccine Partnering Terms and Agreements includes: - Trends in vaccine dealmaking in the biopharma industry since 2007 - Analysis of vaccine deal structure - Access to headline, upfront, milestone and royalty data - Case studies of real-life vaccine deals - Access to over 1,100 vaccine deal documents - The leading vaccine deals by value since 2007 - Most active vaccine dealmakers since 2007 - The leading vaccine partnering resources In Vaccine Partnering Terms and Agreements, the available contracts are listed by: - Company A-Z - Headline value - Stage of development at signing - Deal component type - Therapy target - Specific technology type Each deal title links via weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. Key Questions Answered - What are the precise vaccine rights granted or optioned? - What is actually granted by the agreement to the partner company? - What exclusivity is granted? - What is the payment structure for the deal? - How are sales and payments audited? - What is the deal term? - How are the key terms of the agreement defined? - How are IPRs handled and owned? - Who is responsible for commercialization? - Who is responsible for development, supply, and manufacture? - How is confidentiality and publication managed? - How are disputes to be resolved? - Under what conditions can the deal be terminated? - What happens when there is a change of ownership? - What sublicensing and subcontracting provisions have been agreed? - Which boilerplate clauses does the company insist upon? - Which boilerplate clauses appear to differ from partner to partner or deal type to deal type? - Which jurisdiction does the company insist upon for agreement law? Companies Mentioned - Abbott - Alnylam Pharmaceuticals - Astellas - AstraZeneca - Bavarian Nordic - Baxter International - Bayer - BioCryst Pharmaceuticals - Biogen Idec - Biota Holdings - Boehringer Ingelheim - Bristol-Myers Squibb - CSL - Daiichi Sankyo - Eisai - Elan - Emergent BioSolutions - Genmab - Gilead Sciences - GlaxoSmithKline - Immunomedics - Johnson & Johnson - Kyowa Hakko Kirin - Merck & Co - Merck KGaA - Mitsubishi Tanabe - Morphosys - Novartis - Pfizer - Purdue Research Foundation - Ranbaxy Laboratories - Roche - Shionogi - Spectrum Pharmaceuticals - Takeda Canada - Teva For more information visit http://www.researchandmarkets.com/research/qvn7n4/vaccine About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products.
Threshold Pharmaceuticals' Partner Merck KGaA, Darmstadt, Germany Initiates Phase 1 Dose Escalation Study of TH-302 in Combination With Gemcitabine and Nab-paclitaxel (Abraxane(R)) in Pancreatic Cancer
Marketwire - Thu Mar 27, 6:00AM CDT
Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that Threshold's partner Merck KGaA, Darmstadt, Germany, through its biopharmaceutical division, has initiated a Phase 1 dose escalation study assessing the safety, tolerability and anti-tumor activity of the investigational hypoxia-targeted drug TH-302 in combination with gemcitabine and nab-paclitaxel (Abraxane(R)) in patients with previously untreated, locally advanced unresectable or metastatic pancreatic adenocarcinoma.
Smoking Cessation Partnering 2009-2014 Report Features Everything a Prospective Dealmaker Needs to Know About Partnering
M2 - Thu Mar 27, 5:31AM CDT
Research and Markets (http://www.researchandmarkets.com/research/vvh8g5/smoking_cessation) has announced the addition of the "Smoking Cessation Partnering 2009-2014" report to their offering. Smoking Cessation Partnering 2009-2014 report provides understanding and access to the smoking partnering deals and agreements entered into by the worlds leading healthcare companies. - Trends in smoking cessation partnering deals - Top smoking deals by value - Deals listed by company A-Z, industry sector, stage of development, technology type The report provides an analysis of smoking cessation partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors smoking cessation technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases do not. Companies Mentioned: Normal 0 false false false EN-IE X-NONE X-NONE Abbott Actavis Astellas AstraZeneca Baxter International Boehringer Ingelheim Bristol-Myers Squibb Celgene Daiichi Sankyo Dainippon Sumitomo Eisai Eli Lilly Forest Laboratories GlaxoSmithKline Hospira Johnson & Johnson Kyowa Hakko Kirin Lundbeck Merck KGaA Novo Nordisk Otsuka Pfizer Roche Sanofi Shire Takeda Teva Valeant Warner Chilcott Watson For more information visit http://www.researchandmarkets.com/research/vv..._cessation About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Hearing Disorders Partnering 2009-2014 Study Provides Understanding and Access to the Hearing Disorders Partnering Deals and Agreements
M2 - Wed Mar 26, 11:05AM CDT
Research and Markets (http://www.researchandmarkets.com/research/dljhf4/hearing_disorders) has announced the addition of the "Hearing Disorders Partnering 2009-2014" report to their offering. Hearing Disorders Partnering 2009-2014 report provides understanding and access to the Hearing disorders partnering deals and agreements entered into by the worlds leading healthcare companies. - Trends in Hearing disorders partnering deals - Top Hearing disorders deals by value - Deals listed by company A-Z, industry sector, stage of development, technology type Hearing Disorders Partnering 2009-2014 provides understanding and access to the Hearing disorders partnering deals and agreements entered into by the worlds leading healthcare companies. The report provides an analysis of hearing disorders partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors Hearing disorders technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. Companies Mentioned: Normal 0 false false false EN-IE X-NONE X-NONE Abbott Actavis Aspen Pharmacare Astellas AstraZeneca Baxter International Bayer Boehringer Ingelheim Bristol-Myers Squibb Celgene CSL Daiichi Sankyo Eli Lilly Forest Laboratories GlaxoSmithKline Hospira Johnson & Johnson Kyowa Hakko Kirin Lundbeck Merck KGaA Mitsubishi Tanabe Novo Nordisk Otsuka Pfizer Roche Sanofi Takeda Teva Valeant Watson For more information visit http://www.researchandmarkets.com/research/dl...g_disorder About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Preventative Medicine Partnering 2009-2014 Report Out Now
M2 - Wed Mar 26, 11:00AM CDT
Research and Markets (http://www.researchandmarkets.com/research/xjvn7k/preventative) has announced the addition of the "Preventative Medicine Partnering 2009-2014" report to their offering. Preventative Medicine Partnering 2009-2014 report provides understanding and access to the preventative medicine partnering deals and agreements entered into by the worlds leading healthcare companies. - Trends in preventative medicine partnering deals - Top preventative medicine deals by value - Deals listed by company A-Z, industry sector, stage of development, technology type Preventative Medicine Partnering 2009-2014 provides understanding and access to the preventative medicine partnering deals and agreements entered into by the worlds leading healthcare companies. The report provides an analysis of preventative medicine partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors preventative medicine technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases do not. In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of preventative medicine technologies and products. Companies Mentioned: -Abbott -AstraZeneca -Baxter International -Bayer -Boehringer Ingelheim -Bristol-Myers Squibb -CSL -Daiichi Sankyo -Eli Lilly -Endo Pharmaceuticals -Forest Laboratories -Galderma -Gilead Sciences -Hospira -Johnson & Johnson -Kyowa Hakko Kirin -Lundbeck -Merck KGaA -Mitsubishi Tanabe -Novartis -Novo Nordisk -Otsuka -Pfizer -Roche -Sanofi -Shire -Takeda -Valeant -Warner Chilcott -Watson For more information visit http://www.researchandmarkets.com/research/xj...eventative About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Kemira Oyj: Jari Paasikivi elected as new Chairman of the Board of Directors in the AGM, EUR 0.53 dividend approved
Thomson Reuters ONE - Mon Mar 24, 8:31AM CDT
The Annual General Meeting of Kemira Oyj approved the Board of Directors proposal of EUR 0.53 dividend per share for the financial year 2013. The Annual General Meeting elected six members (previously five) to the Board of Directors. Annual General Meeting reelected Winnie Fok, Juha Laaksonen, Jari Paasikivi and Kerttu Tuomas and elected Wolfgang Buchele and Timo Lappalainen as new members. Jari Paasikivi was elected as the Board's Chairman and Kerttu Tuomas was elected as the Vice Chairman.
Global Specialty Chemicals Market 2014-2018: Trend of Mergers and Acquisitions Expected to Continue in the High Growth Areas of Latin America and the APAC Region
M2 - Fri Mar 07, 6:32AM CST
Research and Markets (http://www.researchandmarkets.com/research/kqdpg3/global_specialty) has announced the addition of the "Global Specialty Chemicals Market 2014-2018" report to their offering. The analysts forecast the Global Specialty Chemicals market to grow at a CAGR of 5.16 percent over the period 2013-2018. One of the key factors contributing to this market growth is the growing demand for specialty chemicals products in the rapidly developing countries of the APAC region. The Global Specialty Chemicals market has also been witnessing the increase in mergers and acquisitions through which key players in the market are increasing their penetration in the emerging economies. However, the increasingly stringent health and environmental regulations could pose a challenge to the growth of this market. Key vendors dominating this space are 3M Company, AkzoNobel NV, Arkema SA, BASF SE, Bayer AG, Clariant AG, Dow Chemical Co., Evonik Industries Inc., Ecolab Inc., E. I. du Pont de Nemours and Co., Henkel AG & Co. KGaA, Koninklijke DSM NV, PPG Industries Inc., Solvay-Rhodia, and Syngenta AG. Other vendors mentioned in the report are Ashland Inc., Avery Dennison Corp., DIC Corp., Eastman Chemical Co., Givaudan SA, Honeywell International Inc., Huntsman Corp., Lonza Group, Lubrizol Corp., Merck KGaA, Momentive Performance Materials Holdings Inc., Monsanto Co., RPM International Inc., Sherwin-Williams Co., Shin-Etsu Chemical Co. Ltd., Toray Industries Inc., Valspar Corp., and Wacker Chemie AG. Commenting on the report, an analyst from the team said: Many SMEs involved in chemical manufacturing are effective in the production of specialty chemicals for niche markets, though they lack in logistics for manufacturing specialty chemicals in bulk. Since the Specialty Chemicals market is highly fragmented, the key players are trying to gain more market share through the mergers and acquisitions of smaller firms. This trend will help the large vendors to grow and improve their networks at a faster pace. Moreover, the mergers and acquisitions strategy will help the bigger players to penetrate the markets in the emerging economies of Latin America and the APAC region. Global chemical manufacturers that have a large geographic presence, diversified product portfolio, and technical expertise for providing VAS are preferred by large industrial consumers. The mergers and acquisitions strategy serves all three main purposes of improving efficiency, diversifying product portfolio, and expanding the vendors' geographic presence. For more information visit http://www.researchandmarkets.com/research/kq..._specialty About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Threshold Pharmaceuticals Reports Fourth Quarter and Year End 2013 Financial and Operational Results
Marketwire - Thu Mar 06, 6:00AM CST
Threshold Pharmaceuticals, Inc. (NASDAQ: THLD), today reported financial results for the fourth quarter and year ended December 31, 2013 and reported on clinical development objectives for TH-302, the Company's investigational hypoxia-targeted drug, which is currently being evaluated in two pivotal Phase 3 clinical trials, one in patients with advanced soft tissue sarcoma and the other in patients with advanced pancreatic cancer. Revenue for the fourth quarter and year ended December 31, 2013 was $3.2 million and $12.5 million, respectively. Net loss for the fourth quarter ended December 31, 2013 was $7.6 million, which included the operating loss of $7.8 million and non-cash income of $0.2 million related to changes in the fair value of the Company's outstanding and exercised warrants that was classified as other income (expense). Net loss for the year ended December 31, 2013 was $28.4 million, which included the operating loss of $26.0 million and non-cash expense of $2.3 million related to changes in the fair value of the Company's outstanding and exercised warrants. As of December 31, 2013, Threshold had $82.0 million in cash, cash equivalents and marketable securities, with no debt outstanding. Subsequent to December 31, 2013, Threshold received a $12.5 million milestone payment, which was earned during the fourth quarter of 2013, under its global license and co-development agreement with Merck KGaA, Darmstadt, Germany. The agreement includes an option for Threshold to co-commercialize TH-302 in the U.S.
Concise Analysis of the Future Prospects of Global Personalized Medicine Market
M2 - Tue Mar 04, 5:49AM CST
Research and Markets (http://www.researchandmarkets.com/research/zpctsr/future_prospects) has announced the addition of the "Concise Analysis of the Future Prospects of Global Personalized Medicine Market" report to their offering. Over the years, the Global Personalized Medicine market has been witnessing the emergence of various tools and technologies from the reputed vendors. For instance, AssureRx Health Inc. launched GeneSightRx ADHD in May 2012, a personalized medicine test for the growing number of children and adults diagnosed with ADHD. Moreover, Bristol-Myers Squibb Co. collaborated with MMRF in December 2012 for advanced personalized medicine for multiple Myeloma. Further, Alacris Theranostics GmbH entered into an agreement with GlaxoSmithKline plc in November 2012 to use ModCell system for early stage cancer research. Further, AltheaDx Inc. launched FLT3 Mutation Assay in October 2012. Agendia N.V. launched ColoPrint microarray-based 18-gene expression signature in June 2012 for predicting the risk of distant recurrence for stage II colon cancer patients. The European Medicines Agency approved Zelboraf, manufactured by F. Hoffmann-La Roche Ltd., in December 2011. Key Topics Covered: 1. Executive Summary 2. List of Abbreviations 3. Introduction 4. Market Research Methodology 5. Scope of the Report 6. Market Landscape 7. Geographical Segmentation 8. Key Leading Countries 9. Vendor Landscape 10. Buying Criteria 11. Market Growth Drivers 12. Drivers and their Impact 13. Market Challenges 14. Impact of Drivers and Challenges 15. Market Trends 16. Key Vendor Analysis 17. Other Reports in this Series Companies Mentioned: - Abbott Laboratories - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Co. - Celgene Corp. - Daiichi Sankyo Co. Ltd. - Danaher Corp. - Eli Lilly and Co. - Evotec AG - F. Hoffmann-La Roche Ltd. - GE Healthcare Ltd. - Genelex Corp. - GlaxoSmithKline plc - Hologic Inc. - Johnson & Johnson - Laboratory Corporation of America Holdings - Life Technologies Corp. - Merck KGaA - Mitsubishi Tanabe Pharma Corp. - Myriad Genetics Inc. - Novartis AG - Novartis AG - PerkinElmer Inc. - Pfizer Inc. - Pfizer Inc. - Quest Diagnostics Inc. - Sanofi S.A. - Sanofi S.A. - Siemens Healthcare - Sigma-Aldrich Corp. - Takeda Pharmaceutical Co. Ltd. - Teva Pharmaceutical Industries Ltd. - Thermo Fisher Scientific Inc. - Transgenomic Inc. For more information visit http://www.researchandmarkets.com/research/zp..._prospects
Infectives Partnering Terms and Agreements Report - 2014 Edition
M2 - Tue Feb 25, 9:46AM CST
Research and Markets (http://www.researchandmarkets.com/research/dxxcsm/infectives) has announced the addition of the "Infectives Partnering Terms and Agreements" report to their offering. The Infectives Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the infectives partnering deals and agreements entered into by the worlds leading healthcare companies. The report provides a detailed understanding and analysis of how and why companies enter infectives partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors infectives technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases do not. Key Topics Covered: Executive Summary Chapter 1 - Introduction Chapter 2 - Trends in infectives dealmaking Chapter 3 - Leading infectives deals Chapter 4 - Bigpharma infectives deals Chapter 5 - Infectives partnering contracts directory Chapter 6 - Infectives dealmaking by indication Chapter 7 - Partnering resource center Companies Mentioned - Abbott - Actavis - Aspen Pharmacare - AstraZeneca - Baxter International - Bayer - Biogen Idec - Boehringer Ingelheim - Bristol-Myers Squibb - Dainippon Sumitomo - Eisai - Eli Lilly - Gilead Sciences - GlaxoSmithKline - Grifols - Hospira - Johnson & Johnson - Kyowa Hakko Kirin - Merck & Co - Merck KGaA - Mitsubishi Tanabe - Novartis - Novo Nordisk - Pfizer - Roche - Sanofi - Servier - Teva - Warner Chilcott - Watson For more information visit http://www.researchandmarkets.com/research/dxxcsm/infectives
TransCelerate BioPharma Inc. Names Annalisa Jenkins as Chair of Its Board of Directors
PR Newswire - Tue Feb 25, 8:00AM CST
TransCelerate BioPharma Inc. ("TransCelerate") today announced the appointment of Annalisa Jenkins, MBBS, MRCP, Executive Vice President and Head of Global Research and Development at Merck Serono (biopharma division of Merck KGaA, Darmstadt, Germany), as Chair of its Board of Directors, effective immediately. Dr. Jenkins, who previously served as a member of the Board of Directors, will work closely with TransCelerate CEO Dr. Dalvir Gill to further the organization's goal of helping the industry expedite the delivery of more high quality medicines to patients. Dr. Jenkins will succeed Paul Stoffels, MD, who had served as the interim Chairman of the Board.
Concise Analysis of the International Chromatography Reagents Market - Forecasts to 2018
M2 - Fri Feb 21, 2:52AM CST
Research and Markets (http://www.researchandmarkets.com/research/qgpjjl/chromatography) has announced the addition of the "Concise Analysis of the International Chromatography Reagents Market - Forecasts to 2018" report to their offering. The market has witnessed a large number of advancements in the design of columns and the development of better performing resins and reagents. The global market is valued at $4,598.0 million in 2013 and is expected to reach $7,609.3 million by 2018, at a CAGR of 10.6%. This report categorizes the market into two broad segments based on application, namely,analytical CR and bioprocess/preparative chromatography reagents. These two application segments are further categorized into CR by type, technique, end users, and geography. For analytical applications, the market by type is categorized into silylation reagents, alkylation reagents, acylation reagents, ion-pairing reagents, solvents, buffers, and solid support. Solvents dominate the market for analytical applications in 2013, closely followed by solid support. The market by type for bioprocess/preparative applications is broadly categorized into solvents, buffers, and solid support.Solid support dominated the market in 2013 with a market share of around 49% of the global bio-process/preparative market. The market by technique is categorized into column and planar chromatography reagents based on bed shape; gas, liquid, and supercritical phase CR based on physical state of mobile phase; and adsorption, partition, ion-exchange, size exclusion and affinity CR based on separation mechanism. Key Topics Covered: 1 Introduction 2 Executive Summary 3 Market Overview 4 Global Market, By Type 5 Global Market,By Bed Shape 6 Global Market,By Physical State Of Mobile Phase 7 Global Market, By Separation Mechanism 8 Global Market, By End Users 9 Geographic Analysis 10 Competitive Landscape 11 Company Profiles Companies Mentioned: - Agilent Technologies - Becton, Dickinson And Company - Bio-Rad Laboratories, INC - Emd Millipore/Merck Millipore (A Divison Of Merck KGAA) - GE Healthcare - Helena Laboratories - Life Technologies - Pall Corporation - Phenomenex, INC - Regis Technologies - Sigma-Aldrich Corporation - Thermo Fisher Scientific - Tosoh Corporation - VWR International - WR Grace & CO - Waters Corporation For more information visit http://www.researchandmarkets.com/research/qg...matography
2013 Report on Biotechnology Deals and Alliances Includes the Most Up to Date Deal and Company Data
M2 - Mon Feb 17, 6:42AM CST
Research and Markets (http://www.researchandmarkets.com/research/9lxjp7/biotechnology) has announced the addition of the "Biotechnology Deals and Alliances of 2013" report to their offering. Using these reports, dealmakers will effectively and efficiently gain insight into the partnering activities of the past year. The report series allows you to view all the partnering and alliances deals announced worldwide. The initial chapters of this report provide an orientation of 2013's dealmaking and business activities. Chapter 1 provides an overview of the trends in dealmaking during 2013 covering trends by deal type, stage of development, technology type and therapeutic indication. Chapter 2 provides a review of the leading deals during 2013. Deals are listed by headline value, signed by Biotechnology and bigbiotech, and most active Biotechnology. Where the deal has an agreement contract published at the SEC a link provides online access to the contract. Chapter 3 provides a comprehensive listing of the top 50 Biotechnology companies with a brief summary followed by a comprehensive listing of 2013 deals, as well as contract documents available in the public domain. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. Chapter 4 provides a comprehensive directory of all partnering deals announced during 2013. In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of technologies and products during 2013. Companies Mentioned: - Abbott - Actavis - Astellas - AstraZeneca - Baxter International - Boehringer Ingelheim - Bristol-Myers Squibb - Celgene - Daiichi Sankyo - Eli Lilly - Endo Pharmaceuticals - Forest Laboratories - GlaxoSmithKline - Grifols - Hospira - Johnson & Johnson - Kyowa Hakko Kirin - Lundbeck - Merck KGaA - Novo Nordisk - Otsuka - Pfizer - Roche - Sanofi - Shire - Takeda - Teva - Valeant - Warner Chilcott - Watson For more information visit http://www.researchandmarkets.com/research/9l...technology About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Cartilage Degeneration - Pipeline Review, H2 2013 Research Report
M2 - Mon Feb 17, 3:39AM CST
Research and Markets (http://www.researchandmarkets.com/research/hzb6kb/cartilage) has announced the addition of the "Cartilage Degeneration - Pipeline Review, H2 2013" report to their offering. 'Cartilage Degeneration - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Cartilage Degeneration, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Cartilage Degeneration. Scope - A snapshot of the global therapeutic scenario for Cartilage Degeneration. - A review of the Cartilage Degeneration products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Cartilage Degeneration pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: Introduction Cartilage Degeneration Overview Therapeutics Development Clinical Stage Products Early Stage Products Cartilage Degeneration - Products under Development by Companies Cartilage Degeneration - Companies Involved in Therapeutics Development Cartilage Degeneration - Therapeutics Assessment Drug Profiles sprifermin - Drug Profile Chondrogen - Drug Profile MSB-CAR-001 - Drug Profile AOD-9604 - Drug Profile THR-166 - Drug Profile ST-03 - Drug Profile Cartilage Degeneration - Recent Pipeline Updates Appendix List of Tables List of Figures Companies Mentioned Sanofi Merck KGaA Mesoblast Limited Calzada Limited Thrasos, Inc. For more information visit http://www.researchandmarkets.com/research/hzb6kb/cartilage About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
ABPI, Merck KGaA, Sanofi and Many More Now Confirmed for SMi Group Big Data in Pharma Event
PRWeb - Tue Feb 04, 5:01AM CST
Two-day event to take place 12th - 13th May 2014 in London featuring leading pharma and biotech experts.The event will aim to help companies understand how to leverage Big Data by exploiting its potential to create better medicine and generate new revenue streams.
Shell to stop Alaska exploratory drilling in 2014
EFE News Services - Thu Jan 30, 1:22PM CST
Royal Dutch Shell will halt its exploration program for the U.S. state of Alaska in 2014, new CEO Ben van Beurden announced Thursday.
SMi Group announces inaugural Big Data in Pharma event
PRWeb - Fri Jan 24, 7:10AM CST
The SMi Group has announced the launch of its inaugural Big Data in Pharma event in response to market demand. The two-day event will aim to help companies understand how to leverage Big Data by exploiting its potential to create better medicine and generate new revenue streams.
'Why De-Registered Parties Joined PDP'
by Misbahu Bashir - All Africa Global Media - Tue Jan 21, 3:32AM CST
Chairman of the defunct United Nigeria Peoples Party (UNPP) Alhaji Inuwa Ahmed, yesterday at a media briefing in Kaduna explained why 23 de-registered political parties joined the ruling People's Democratic Party (PDP).
Stria Unveils Cost-Cutting Lithium Processing Technologies for Its Pontax and Wilcox Lithium Projects
Marketwire Canada - Tue Jan 14, 8:13AM CST
Stria Capital Inc. (TSX VENTURE:SRA) ("Stria") owner of the Pontax Lithium and Wilcox Lithium Projects, (see news release dated January 6, 2014 available at www.sedar.com), in Canada and the United States, announced today its plans to introduce proprietary on-site processing technologies that produce high purity lithium chloride directly from spodumene ore on an environmentally sustainable, cost-reduced basis.
Personalized Medicine in Oncology Partnering Terms and Agreements Report 2014
M2 - Fri Jan 10, 8:18AM CST
Research and Markets (http://www.researchandmarkets.com/research/f8nt2k/personalized) has announced the addition of the "Personalized Medicine in Oncology Partnering Terms and Agreements" report to their offering. The Personalized Medicine in Oncology Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the personalized medicine in oncology partnering agreements entered into by the worlds leading healthcare companies. The report provides a detailed understanding and analysis of how and why companies enter personalized medicine in oncology partnering deals. The majority of deals are discovery stage whereby the licensee obtains a right or an option right to license the licensors personalized medicine technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not. Key Topics Covered: Chapter 1 - Introduction Chapter 2 - Trends in personalized medicine in oncology dealmaking Chapter 3 - Leading personalized medicine in oncology deals Chapter 4 - Big pharma personalized medicine in oncology deals Chapter 5 - Personalized medicine in oncology dealmaking directory Chapter 6 - Personalized medicine in oncology dealmaking directory by specific technology type Chapter 7 - Partnering resource center Companies Mentioned - Abbott - Amgen - Astellas - AstraZeneca - Bayer - Biogen Idec - Boehringer Ingelheim - Bristol-Myers Squibb - Celgene - Eisai - Eli Lilly - Gilead Sciences - GlaxoSmithKline - Johnson & Johnson - Merck & Co - Merck KGaA - Novartis - Pfizer - Roche - Sanofi - Servier - Teva For more information visit http://www.researchandmarkets.com/research/f8...rsonalized
Vaccine Partnering Terms and Agreements - 2014 Report
M2 - Fri Jan 10, 4:25AM CST
Research and Markets (http://www.researchandmarkets.com/research/qvn7n4/vaccine) has announced the addition of the "Vaccine Partnering Terms and Agreements" report to their offering. The report provides comprehensive understanding and unprecedented access to the vaccine partnering deals and agreements entered into by the worlds leading healthcare companies. The report provides a detailed understanding and analysis of how and why companies enter vaccine partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors vaccine technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. The report also includes adjuvant deals and alliances. This report contains over 1,100 links to online copies of actual vaccine deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal. Vaccine Partnering Terms and Agreements includes: - Trends in vaccine dealmaking in the biopharma industry since 2007 - Analysis of vaccine deal structure - Access to headline, upfront, milestone and royalty data - Case studies of real-life vaccine deals - Access to over 1,100 vaccine deal documents - The leading vaccine deals by value since 2007 - Most active vaccine dealmakers since 2007 - The leading vaccine partnering resources In Vaccine Partnering Terms and Agreements, the available contracts are listed by: - Company A-Z - Headline value - Stage of development at signing - Deal component type - Therapy target - Specific technology type Each deal title links via weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. Key Questions Answered - What are the precise vaccine rights granted or optioned? - What is actually granted by the agreement to the partner company? - What exclusivity is granted? - What is the payment structure for the deal? - How are sales and payments audited? - What is the deal term? - How are the key terms of the agreement defined? - How are IPRs handled and owned? - Who is responsible for commercialization? - Who is responsible for development, supply, and manufacture? - How is confidentiality and publication managed? - How are disputes to be resolved? - Under what conditions can the deal be terminated? - What happens when there is a change of ownership? - What sublicensing and subcontracting provisions have been agreed? - Which boilerplate clauses does the company insist upon? - Which boilerplate clauses appear to differ from partner to partner or deal type to deal type? - Which jurisdiction does the company insist upon for agreement law? Companies Mentioned - Abbott - Alnylam Pharmaceuticals - Astellas - AstraZeneca - Bavarian Nordic - Baxter International - Bayer - BioCryst Pharmaceuticals - Biogen Idec - Biota Holdings - Boehringer Ingelheim - Bristol-Myers Squibb - CSL - Daiichi Sankyo - Eisai - Elan - Emergent BioSolutions - Genmab - Gilead Sciences - GlaxoSmithKline - Immunomedics - Johnson & Johnson - Kyowa Hakko Kirin - Merck & Co - Merck KGaA - Mitsubishi Tanabe - Morphosys - Novartis - Pfizer - Purdue Research Foundation - Ranbaxy Laboratories - Roche - Shionogi - Spectrum Pharmaceuticals - Takeda Canada - Teva For more information visit http://www.researchandmarkets.com/research/qvn7n4/vaccine About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products.
